Literature DB >> 32122615

Poly(I:C) augments inactivated influenza virus-chitosan nanovaccine induced cell mediated immune response in pigs vaccinated intranasally.

Sankar Renu1, Ninoshkaly Feliciano-Ruiz1, Shristi Ghimire1, Yi Han1, Jennifer Schrock1, Santosh Dhakal1, Veerupaxagouda Patil1, Steven Krakowka2, Gourapura J Renukaradhya3.   

Abstract

To improve the innate and adaptive immune responses elicited by a killed/inactivated swine influenza virus antigen (KAg)-loaded chitosan nanoparticles (CS NPs-KAg), we used the adjuvant, poly(I:C). The formulated CS NPs-KAg and CS NPs-poly(I:C) had a net surface charge of +30.7 mV and +25.1 mV, respectively. The CS NPs-KAg was coadministered with CS NPs-poly(I:C) (chitosan nanovaccine) as intranasal mist. Vaccinations enhanced homologous (H1N2-OH10) and heterologous (H1N1-OH7) hemagglutination inhibition (HI) titers in both vaccinated and virus-challenged animals compared to the control soluble poly(I:C) vaccinated pigs. In addition, the chitosan nanovaccine induced the proliferation of antigen-specific IFNγ secreting T-helper/memory and γδ T cells compared to control poly(I:C) group; and an increased Th1 (IFNγ, IL-6 and IL-2) and Th2 (IL-10 and IL-13) cytokines mRNA expression in the tracheobronchial lymph nodes compared to lymphoid tissues obtained from pigs given commercial influenza vaccine. The virus load in nasal passages and microscopic lung lesions were partially reduced by both chitosan nanovaccine and commercial vaccine. The HA gene homology between the vaccine and challenge viruses indicated that the chitosan nanovaccine induced a cross-protective immune response. In conclusion, coadministration of CS NPs-poly(I:C) with CS NPs-KAg augmented the cross-reactive specific HI titers and the cell-mediated immune responses in pigs.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chitosan nanovaccine; Innate and adaptive immunity; Intranasal delivery; Pigs; Poly(I:C); Swine influenza virus

Year:  2020        PMID: 32122615     DOI: 10.1016/j.vetmic.2020.108611

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  9 in total

1.  Gut Microbiota of Obese Children Influences Inflammatory Mucosal Immune Pathways in the Respiratory Tract to Influenza Virus Infection: Optimization of an Ideal Duration of Microbial Colonization in a Gnotobiotic Pig Model.

Authors:  Sankar Renu; Loic Deblais; Veerupaxagouda Patil; Jennifer Schrock; Dipak Kathayat; Vishal Srivastava; Ninoshkaly Feliciano-Ruiz; Yi Han; Anikethana Ramesh; Yashavanth S Lakshmanappa; Shristi Ghimire; Santosh Dhakal; Gireesh Rajashekara; Gourapura J Renukaradhya
Journal:  Microbiol Spectr       Date:  2022-05-17

2.  Immunity and Protective Efficacy of Mannose Conjugated Chitosan-Based Influenza Nanovaccine in Maternal Antibody Positive Pigs.

Authors:  Sankar Renu; Ninoshkaly Feliciano-Ruiz; Veerupaxagouda Patil; Jennifer Schrock; Yi Han; Anikethana Ramesh; Santosh Dhakal; Juliette Hanson; Steven Krakowka; Gourapura J Renukaradhya
Journal:  Front Immunol       Date:  2021-03-04       Impact factor: 7.561

Review 3.  Chitosan Nanoparticle Based Mucosal Vaccines Delivered Against Infectious Diseases of Poultry and Pigs.

Authors:  Sankar Renu; Gourapura J Renukaradhya
Journal:  Front Bioeng Biotechnol       Date:  2020-11-13

Review 4.  Promising Adjuvants and Platforms for Influenza Vaccine Development.

Authors:  Wandi Zhu; Chunhong Dong; Lai Wei; Bao-Zhong Wang
Journal:  Pharmaceutics       Date:  2021-01-07       Impact factor: 6.321

Review 5.  Future perspectives on swine viral vaccines: where are we headed?

Authors:  Tanja Opriessnig; Ashley A Mattei; Anbu K Karuppannan; Patrick G Halbur
Journal:  Porcine Health Manag       Date:  2021-01-04

6.  Supplementation of H7N9 Virus-Like Particle Vaccine With Recombinant Epitope Antigen Confers Full Protection Against Antigenically Divergent H7N9 Virus in Chickens.

Authors:  Dexin Kong; Taoran Chen; Xiaolong Hu; Shaorong Lin; Yinze Gao; Chunmei Ju; Ming Liao; Huiying Fan
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

7.  Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model.

Authors:  Kairat Tabynov; Meruert Babayeva; Tair Nurpeisov; Gleb Fomin; Temirzhan Nurpeisov; Ulbossyn Saltabayeva; Sankar Renu; Gourapura J Renukaradhya; Nikolai Petrovsky; Kaissar Tabynov
Journal:  Front Immunol       Date:  2022-03-15       Impact factor: 7.561

Review 8.  Progress in the Development of Universal Influenza Vaccines.

Authors:  Wenqiang Sun; Tingrong Luo; Wenjun Liu; Jing Li
Journal:  Viruses       Date:  2020-09-17       Impact factor: 5.048

Review 9.  A review of the antiviral activity of Chitosan, including patented applications and its potential use against COVID-19.

Authors:  Nisrein Jaber; Mayyas Al-Remawi; Faisal Al-Akayleh; Najah Al-Muhtaseb; Ibrahim S I Al-Adham; Phillip J Collier
Journal:  J Appl Microbiol       Date:  2021-07-26       Impact factor: 4.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.